Metraipolis › archive › dc_e1df01705fcb

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma — Europe PMC PMID:42143334

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42143334
DOI: 10.1186/s13046-[numero omesso]-3
License (as archived): solo-consultazione
Archived: 2026-11-02T05:04:53.805Z
SHA-256 of the archived text: 58c0345c6758cc7e122616807bb3259e158b2e25738fedf9d51c56c240a2182b
Stable URL of this page: https://metraipolis.com/documento/dc_e1df01705fcb

How to cite

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma — Europe PMC PMID:42143334 — Europe PMC (en), https://europepmc.org/article/MED/42143334 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e1df01705fcb (Metraipolis archive dc_e1df01705fcb, sha256 58c0345c6758cc7e122616807bb3259e158b2e25738fedf9d51c56c240a2182b)

BibTeX

@misc{dce1df01705fcb,
  title = {Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma — Europe PMC PMID:42143334},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42143334},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e1df01705fcb; sha256 58c0345c6758cc7e122616807bb3259e158b2e25738fedf9d51c56c240a2182b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42143334. Agents can read the archived copy with the MCP tool read_document.